A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis

Table 6

Summary of proof of concept articles on point of care tests for Trichomonas vaginalis from 2010 to 2015.

Study authors and year	Summary of results; (summaries are based on descriptions in abstracts and articles)	Performance
Pearce et al. 2013 [51]	Electrochemical endpoint assay prototype: a single card performs target DNA extraction, amplification, and electrochemical detection via electrochemical endpoint detection. This prototype is designed to work with the Atlas io platform	Sensitivity and specificity of 95.5% (42/44) and 95.7% (44/46), respectively; Limit of detection: 5 TV cells; No cross-reactivity with the nucleic acids from organisms commonly associated with the genitourinary tract
Spizz et al. 2012 [47]	Rheonix CARD STI CARD assay: a patented lamination process incorporates all pumps, valves, microchannels, and reaction compartments into an inexpensive disposable plastic device that automatically performs all assay steps. Amplicons detected with Reverse Dot Blot assay	Able to detect a minimum of 10 copies of each of the four pathogens (N. gonorrhoeae, C. trachomatis, T. pallidum,and T. vaginalis)